About this trial
The Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) trial will be a 6-year (4-year enrollment), open label, phase-3, multi-center, early in-hospital phase randomized trial utilizing burn centers from within the LITES network and will enroll approximately 750 injured adult patients who have suffered large 2nd or 3rd degree thermal burns on at least 20% of their body surface requiring burn resusciation. The objective is to determine if initiating plasma resuscitation as soon as possible upon arrival to an emergency department or burn unit is the most effective resuscitation for those who have experienced large thermal burns and significantly reduces the morbidity and mortality attributable to post-injury complications as compared to standard in-hospital resuscitation practice.
Eligibility criteria
Qualifiers
Estimated ≥ 20% Total Body Surface Area burn/thermal injury with 2nd or 3rd degree depth
Anticipated admission to burn ICU
Disqualifiers
Estimated rBaux score <55
Not expected to survive >24 hours
Wearing NO PREEVENT opt-out bracelet
Age > 75 or < 18 years of age
Trial design
Treatments tested in this trial
- Plasma
- Standard care
Treatment groups
Sponsors and collaborators
Jason Sperry
Lead sponsor
University of Pittsburgh
Sponsor institution
United States Department of Defense
Collaborator